(Q35619482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

review article

1 reference

title

A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference

Robertson JF

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

language of work or name

English

0 references

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

17 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

page(s)

215-222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14703069%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/b:brea.0000004375.17920.0b

17 November 2019

exact match

0 references

cites work

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

Tumor characteristics and clinical outcome of elderly women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Aromatase inhibitor development for treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Estrogen receptors and the pattern of relapse in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Estrogen Receptor and Natural Course of Breast Cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Metastatic pattern and response to endocrine therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Development and validation of prognostic models in metastatic breast cancer: a GOCS study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000004375.17920.0B

7 January 2021